Biotech Amarin is gearing up for the launch of its triglyceride-lowering drug Vascepa. The drug is slated to hit the market in the coming weeks and will go up against GlaxoSmithKline's Lovaza and AbbVie's drugs Tricor and Trilipix. Investors are waiting to see whether Vascepa can fulfill the blockbuster destiny many predict, or if the company will fall flat on its face. Many biotechs of late -- including obesity drugmaker VIVUS and cancer-focused biotech Dendreon -- have shown that launching a drug is much, much harder than it looks.
So, investors -- will Amarin succeed or fail?
In this video, health care analyst Max Macaluso discusses his outlook for this stock as the launch date looms.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the Vascepa's success is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with this premium research report. Click here now to keep reading.
The article Amarin's Drug Launch: Mega Hit or Epic Fail? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.